A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice

Antiviral Research

Volumn 143, Issue , 2017, Pages 97-105

  Wang, Yang ^a   Wu, Jialing ^a   Xue, Chunyi ^a   Wu, Zhihui ^a   Lin, Ying ^a   Wei, Ying ^a   Wei, Xiaona ^a   Qin, Jianru ^a   Zhang, Yun ^a   Wen, Zhifen ^a   Chen, Li ^a   Liu, George Dacai ^b   Cao, Yongchang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Firstline Biopharmaceuticals Corporation   (United States)

Author keywords

Cross protection; H7N9; Hemagglutinin; Influenza A virus; Transmembrane domain; Trimerization

Indexed keywords

CROSS REACTING ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN G; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT VACCINE; HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; INACTIVATED VACCINE; RECOMBINANT PROTEIN; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; HUMAN; HUMAN CELL; INFECTION PREVENTION; INFLUENZA A VIRUS (H7N9); INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; VIROGENESIS; VIRUS INACTIVATION; VIRUS LOAD; WEIGHT REDUCTION; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHICKEN; CROSS PROTECTION; CROSS REACTION; DISEASE MODEL; DOG; DRUG EFFECTS; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEK293 CELL LINE; IMMUNOLOGY; INFLAMMATION; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H5N1); LUNG; MDCK CELL LINE; ORTHOMYXOVIRUS INFECTION; PATHOGENICITY; PATHOLOGY; PHYLOGENY; SURVIVAL RATE; VACCINATION; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; CHICKENS; CROSS PROTECTION; CROSS REACTIONS; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HEK293 CELLS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; LUNG; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PHYLOGENY; PROTEIN DOMAINS; RECOMBINANT PROTEINS; SURVIVAL RATE; VACCINATION; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VIRAL LOAD; WEIGHT LOSS;

EID: 85017611867     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2017.03.029     Document Type: Article

References (30)

1. Bao, C.J., Cui, L.B., Zhou, M.H., Hong, L., Gao, G.F., Wang, H., Live-animal markets and influenza A (H7N9) virus infection. N. Engl. J. Med. 368 (2013), 2337–2339.
2. Belser, J.A., Gustin, K.M., Pearce, M.B., Maines, T.R., Zeng, H., Pappas, C., Sun, X., Carney, P.J., Villanueva, J.M., Stevens, J., Katz, J.M., Tumpey, T.M., Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature 501 (2013), 556–559.
3. Couch, R.B., Patel, S.M., Wade-Bowers, C.L., Nino, D., A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PloS One, 7, 2012, e49704.
4. Cox, R.J., Madhun, A.S., Hauge, S., Sjursen, H., Major, D., Kuhne, M., Hoschler, K., Saville, M., Vogel, F.R., Barclay, W., Donatelli, I., Zambon, M., Wood, J., Haaheim, L.R., A phase I clinical trial of a PER.C6 (R) cell grown influenza H7 virus vaccine. Vaccine 27 (2009), 1889–1897.
5. Francis, T. Jr., Vaccination against influenza. Bull. World Health Organ. 8 (1953), 725–741.
6. Gao, R., Cao, B., Hu, Y., Feng, Z., Wang, D., Hu, W., Chen, J., Jie, Z., Qiu, H., Xu, K., Xu, X., Lu, H., Zhu, W., Gao, Z., Xiang, N., Shen, Y., He, Z., Gu, Y., Zhang, Z., Yang, Y., Zhao, X., Zhou, L., Li, X., Zou, S., Zhang, Y., Li, X., Yang, L., Guo, J., Dong, J., Li, Q., Dong, L., Zhu, Y., Bai, T., Wang, S., Hao, P., Yang, W., Zhang, Y., Han, J., Yu, H., Li, D., Gao, G.F., Wu, G., Wang, Y., Yuan, Z., Shu, Y., Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368 (2013), 1888–1897.
7. Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G., Webster, R.G., A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 6108–6113.
8. Houser, K., Subbarao, K., Influenza vaccines: challenges and solutions. Cell Host Microbe 17 (2015), 295–300.
9. Impagliazzo, A., Milder, F., Kuipers, H., Wagner, M.V., Zhu, X., Hoffman, R.M., van Meersbergen, R., Huizingh, J., Wanningen, P., Verspuij, J., de Man, M., Ding, Z., Apetri, A., Kukrer, B., Sneekes-Vriese, E., Tomkiewicz, D., Laursen, N.S., Lee, P.S., Zakrzewska, A., Dekking, L., Tolboom, J., Tettero, L., van Meerten, S., Yu, W., Koudstaal, W., Goudsmit, J., Ward, A.B., Meijberg, W., Wilson, I.A., Radosevic, K., A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349 (2015), 1301–1306.
10. Kanekiyo, M., Wei, C.J., Yassine, H.M., McTamney, P.M., Boyington, J.C., Whittle, J.R., Rao, S.S., Kong, W.P., Wang, L., Nabel, G.J., Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499 (2013), 102–106.
11. Kang, S.M., Guo, L.Z., Skountzou, I., Compans, R.W., Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J. Virol. 78 (2004), 9624–9632.
12. Lam, T.T., Zhou, B., Wang, J., Chai, Y., Shen, Y., Chen, X., Ma, C., Hong, W., Chen, Y., Zhang, Y., Duan, L., Chen, P., Jiang, J., Zhang, Y., Li, L., Poon, L.L., Webby, R.J., Smith, D.K., Leung, G.M., Peiris, J.S., Holmes, E.C., Guan, Y., Zhu, H., Dissemination, divergence and establishment of H7N9 influenza viruses in China. Nature 522 (2015), 102–105.
13. Lin, S.C., Huang, M.H., Tsou, P.C., Huang, L.M., Chong, P., Wu, S.C., Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PloS One, 6, 2011, e20052.
14. Liu, Q., Liu, K., Xue, C., Zhou, J., Li, X., Luo, D., Zheng, J., Xu, S., Liu, G.D., Cao, Y., Recombinant influenza H1, H5 and H9 hemagglutinins containing replaced H3 hemagglutinin transmembrane domain showed enhanced heterosubtypic protection in mice. Vaccine 32 (2014), 3041–3049.
15. Liu, Q.L., Xue, C.Y., Zheng, J., Liu, K., Wang, Y., Wei, Y., Liu, G.D., Cao, Y.C., Influenza bivalent vaccine comprising recombinant H3 hemagglutinin (HA) and H1 HA containing replaced H3 hemagglutinin transmembrane domain exhibited improved heterosubtypic protection immunity in mice. Vaccine 33 (2015), 4035–4040.
16. Liu, T., Bi, Z., Wang, X., Li, Z., Ding, S., Bi, Z., Wang, L., Pei, Y., Song, S., Zhang, S., Wang, J., Sun, D., Pang, B., Sun, L., Jiang, X., Lei, J., Yuan, Q., Kou, Z., Yang, B., Shu, Y., Yang, L., Li, X., Lu, K., Liu, J., Zhang, T., Xu, A., One family cluster of avian influenza A(H7N9) virus infection in Shandong, China. BMC Infect. Dis., 14, 2014, 98.
17. Lu, X.H., Tumpey, T.M., Morken, T., Zaki, S.R., Cox, N.J., Katz, J.M., A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J. Virol. 73 (1999), 5903–5911.
18. Organization, W.H., Human Infection with Avian Influenza A(H7N9) Virus – China. 17 November 2016 http://www.who.int/csr/don/17-november-2016-ah7n9-china/en/ (Accessed).
19. Pawar, S.D., Murtadak, V.B., Kale, S.D., Shinde, P.V., Parkhi, S.S., Evaluation of different inactivation methods for high and low pathogenic avian influenza viruses in egg-fluids for antigen preparation. J. Virol. Methods 222 (2015), 28–33.
20. Schultze, V., D'Agosto, V., Wack, A., Novicki, D., Zorn, J., Hennig, R., Safety of MF59 adjuvant. Vaccine 26 (2008), 3209–3222.
21. Wang, K., Holtz, K.M., Anderson, K., Chubet, R., Mahmoud, W., Cox, M.M., Expression and purification of an influenza hemagglutinin–one step closer to a recombinant protein-based influenza vaccine. Vaccine 24 (2006), 2176–2185.
22. Watanabe, T., Watanabe, S., Maher, E.A., Neumann, G., Kawaoka, Y., Pandemic potential of avian influenza A (H7N9) viruses. Trends Microbiol. 22 (2014), 623–631.
23. Wei, C.J., Xu, L., Kong, W.P., Shi, W., Canis, K., Stevens, J., Yang, Z.Y., Dell, A., Haslam, S.M., Wilson, I.A., Nabel, G.J., Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J. Virol. 82 (2008), 6200–6208.
24. Weldon, W.C., Wang, B.Z., Martin, M.P., Koutsonanos, D.G., Skountzou, I., Compans, R.W., Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PloS One, 5, 2010.
25. Wong, S.S., Jeevan, T., Kercher, L., Yoon, S.W., Petkova, A.M., Crumpton, J.C., Franks, J., Debeauchamp, J., Rubrum, A., Seiler, P., Krauss, S., Webster, R., Webby, R.J., A single dose of whole inactivated H7N9 influenza vaccine confers protection from severe disease but not infection in ferrets. Vaccine 32 (2014), 4571–4577.
26. Wong, S.S., Webby, R.J., Traditional and new influenza vaccines. Clin. Microbiol. Rev. 26 (2013), 476–492.
27. Xu, S., Zhou, J., Liu, K., Liu, Q., Xue, C., Li, X., Zheng, J., Luo, D., Cao, Y., Mutations of two transmembrane cysteines of hemagglutinin (HA) from influenza A H3N2 virus affect HA thermal stability and fusion activity. Virus Genes 47 (2013), 20–26.
28. Xu, S., Zhou, J., Liu, Q., Liu, K., Xue, C., Li, X., Zheng, J., Luo, D., Cao, Y., Evidences for the existence of intermolecular disulfide-bonded oligomers in the H3 hemagglutinins expressed in insect cells. Virus Genes 48 (2014), 304–311.
29. Zhou, J., Xu, S., Ma, J., Lei, W., Liu, K., Liu, Q., Ren, Y., Xue, C., Cao, Y., Recombinant influenza A H3N2 viruses with mutations of HA transmembrane cysteines exhibited altered virological characteristics. Virus Genes 48 (2014), 273–282.
30. Zhu, H., Wang, D., Kelvin, D.J., Li, L., Zheng, Z., Yoon, S.W., Wong, S.S., Farooqui, A., Wang, J., Banner, D., Chen, R., Zheng, R., Zhou, J., Zhang, Y., Hong, W., Dong, W., Cai, Q., Roehrl, M.H., Huang, S.S., Kelvin, A.A., Yao, T., Zhou, B., Chen, X., Leung, G.M., Poon, L.L., Webster, R.G., Webby, R.J., Peiris, J.S., Guan, Y., Shu, Y., Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science 341 (2013), 183–186.